<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01334801</url>
  </required_header>
  <id_info>
    <org_study_id>09-006757</org_study_id>
    <nct_id>NCT01334801</nct_id>
  </id_info>
  <brief_title>Biomarkers in Aortic Stenosis - B.A.S.S.</brief_title>
  <acronym>BASS</acronym>
  <official_title>Biomarkers in Aortic Stenosis, Hypertrophic Cardiomyopathy, Mitral Regurgitation, Aortic Regurgitation, Prosthetic Heart Valve Dysfunction, and Tricuspid Regurgitation From Pacemaker Leads Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine whether or not new blood test(s) can determine the&#xD;
      severity of heart conditions. Aortic stenosis, hypertrophic cardiomyopathy, mitral&#xD;
      regurgitation, aortic regurgitation, artificial heart valve regurgitation or stenosis, and&#xD;
      tricuspid valve regurgitation associated with pacemaker leads are the cardiac disorders under&#xD;
      study. The blood tests involve analysis for von Willebrand Factor antigen and activity, von&#xD;
      Willebrand Factor multimers, and brain natriuretic peptide (BNP) levels. The results of the&#xD;
      blood tests will be compared to the information from the clinically-indicated echocardiogram&#xD;
      and one blood test compared to another.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with aortic stenosis, hypertrophic cardiomyopathy, mitral regurgitation, aortic&#xD;
      regurgitation, artificial heart valve regurgitation or stenosis, and tricuspid valve&#xD;
      regurgitation associated with pacemaker leads who are referred for clinically-indicated&#xD;
      echocardiographic exams at Mayo Clinic, in Jacksonville, Florida will be screened for&#xD;
      participation in the study. The plan is to have 292 people take part in this study. This&#xD;
      minimal risk study will consist of the recording of patient data, activity and bleeding&#xD;
      questionnaires, and collection and analysis of blood samples. Each blood sample will be&#xD;
      analyzed for von Willebrand Factor antigen and activity, and von Willebrand Factor multimers,&#xD;
      and BNP. Blood samples will be sent to the Mayo Special Coagulation Lab for analysis.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      This study seeks to assess the degree of association of the von Willebrand Factor activity&#xD;
      indices and BNP to the severity of cardiac lesions, and to note a relationship between&#xD;
      acquired bleeding the the hematologic abnormalities. Plasma will be stored in attempt to&#xD;
      develop new in vitro tests of von Willebrand factor (VWF) activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Correlation of Von Willebrand Multimer ratio to cardiac lesion severity</measure>
    <time_frame>2 years</time_frame>
    <description>To accomplish the specific aims, the investigators propose to collect clinical and echocardiographic data, and blood samples for von Willebrand Factor antigen and activity, von Willebrand Factor multimers, and BNP in patients with aortic stenosis, or aortic or mitral valve prosthesis, mitral regurgitation, hypertrophic cardiomyopathy, aortic regurgitation, and tricuspid regurgitation associated with pacemaker or defibrillator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of other VWF activity measures with cardiac lesion severity.</measure>
    <time_frame>2 years</time_frame>
    <description>Comprehensively analyze the ability of VWF indices to discriminate severe from non-severe valvular disease, prosthetic valve dysfunction, and describe the prevalence of VWF abnormalities in this wide range of cardiac lesions associated with intravascular turbulence.</description>
  </secondary_outcome>
  <number_of_groups>11</number_of_groups>
  <enrollment type="Anticipated">403</enrollment>
  <condition>Aortic Stenosis</condition>
  <condition>Disorder of Prosthetic Cardiac Valve</condition>
  <condition>Aortic Valve Insufficiency</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Hypertrophic Cardiomyopathy</condition>
  <condition>Tricuspid Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>Aortic Stenosis</arm_group_label>
    <description>Restricted aortic valve motion and a peak Doppler aortic velocity &gt; 2.5 m/sec blood draw</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aortic regurgitation</arm_group_label>
    <description>Echocardiographic and Doppler evaluation revealing aortic regurgitation with data adequate to calculate regurgitant volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aortic valve replacement</arm_group_label>
    <description>Mechanical or biological aortic valve replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitral regurgitation</arm_group_label>
    <description>Echocardiographic and Doppler evaluation revealing mitral regurgitation with data adequate to calculate regurgitant volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitral valve replacement</arm_group_label>
    <description>Mechanical or biological mitral valve replacement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertrophic cardiomyopathy</arm_group_label>
    <description>Patients with known hypertrophic cardiomyopathy who are referred for clinically indicated echocardiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe TR with pacemaker / ICD lead</arm_group_label>
    <description>Patients referred for clinically indicated echocardiography who have severe tricuspid regurgitation associated with a pacemaker or defibrillator lead documented by echocardiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prosthetic valve dysfunction</arm_group_label>
    <description>Patients with prior heart valve replacement or repair referred for clinically indicated echocardiography who demonstrate stenosis, regurgitation, dehiscence.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal controls</arm_group_label>
    <description>Patients with no heart murmur or history of valve replacement, stenosis, regurgitation, or hypertrophic cardiomyopathy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Left ventricular assist device patients</arm_group_label>
    <description>Patients with previously implanted LVAD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Renal dialysis patients</arm_group_label>
    <description>Patients on hemodialysis, peritoneal dialysis, or chronic kidney disease with dialysis fistula to be created.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:&#xD;
BNP (Brain Natriuretic Peptide)&#xD;
(PFA) Platelet Function Analyzer 100&#xD;
von Willebrand Factor (vWF) antigen&#xD;
(vWF) multimers&#xD;
(vWF) *activity by latex aggregation&#xD;
Plasma stored for development of new testing approaches</description>
    <arm_group_label>Aortic Stenosis</arm_group_label>
    <arm_group_label>Aortic regurgitation</arm_group_label>
    <arm_group_label>Aortic valve replacement</arm_group_label>
    <arm_group_label>Hypertrophic cardiomyopathy</arm_group_label>
    <arm_group_label>Mitral regurgitation</arm_group_label>
    <arm_group_label>Mitral valve replacement</arm_group_label>
    <arm_group_label>Prosthetic valve dysfunction</arm_group_label>
    <arm_group_label>Severe TR with pacemaker / ICD lead</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cardiology, referred for clinically-indicated echocardiograms&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with mild, moderate, or severe aortic stenosis or aortic or mitral&#xD;
             prosthesis. Patients with aortic or mitral regurgitation. patients with hypertrophic&#xD;
             cardiomyopathy. Patients with dysfunctional heart valve replacement or repair.&#xD;
             Patients with severe tricuspid regurgitation associated with pacemaker or&#xD;
             defibrillator lead. Ten normal control patients who will not be required to have&#xD;
             echocardiography&#xD;
&#xD;
          -  referred for a clinically indicated echocardiogram; the echo must be of good quality&#xD;
             and specifically have patient height, weight, left ventricular outflow tract diameter,&#xD;
             subaortic velocity profile by Doppler, and aortic transvalvular continuous wave&#xD;
             Doppler velocity profile. For mitral regurgitation and aortic regurgitation the data&#xD;
             must be adequate to allow calculation of regurgitant volume. For hypertrophic&#xD;
             cardiomyopathy, a recording of left ventricular outflow tract peak velocity must be&#xD;
             recorded&#xD;
&#xD;
          -  21 years or older&#xD;
&#xD;
          -  patients with aortic stenosis, defined as peak aortic velocity greater than 2.5 m/sec&#xD;
             with evidence of aortic valve thickening, or an aortic or mitral valve prosthesis&#xD;
&#xD;
          -  able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Missing or inadequate echocardiographic data&#xD;
&#xD;
          -  inability to give informed consent&#xD;
&#xD;
          -  inability to provide a research blood sample&#xD;
&#xD;
          -  hemoglobin less than 8&#xD;
&#xD;
          -  severe valvular regurgitation&#xD;
&#xD;
          -  stenosis of the mitral valve&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph L Blackshear, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carolyne Stevens</last_name>
    <email>Thomas.Carolyne@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 12, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2011</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Joseph L. Blackshear</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>aortic stenosis</keyword>
  <keyword>von Willebrand factor</keyword>
  <keyword>mitral valve replacement</keyword>
  <keyword>aortic valve replacement</keyword>
  <keyword>prosthetic valve dysfunction</keyword>
  <keyword>brain natriuretic peptide</keyword>
  <keyword>mitral valve regurgitation</keyword>
  <keyword>aortic valve regurgitation</keyword>
  <keyword>hypertrophic cardiomyopathy</keyword>
  <keyword>tricuspid insufficiency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Cardiomyopathy, Hypertrophic</mesh_term>
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Aortic Valve Insufficiency</mesh_term>
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

